Cargando…

Dual therapy for Helicobacter pylori infection

Bismuth-containing quadruple therapy (BQT) has long been recommended for Helicobacter pylori (H. pylori) eradication in China. Meanwhile, in the latest national consensus in China, dual therapy (DT) comprising an acid suppressor and amoxicillin has also been recommended. In recent years, the eradica...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Miao, Liu, Jing, Zuo, Xiuli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106215/
https://www.ncbi.nlm.nih.gov/pubmed/36805362
http://dx.doi.org/10.1097/CM9.0000000000002565
_version_ 1785026381001785344
author Duan, Miao
Liu, Jing
Zuo, Xiuli
author_facet Duan, Miao
Liu, Jing
Zuo, Xiuli
author_sort Duan, Miao
collection PubMed
description Bismuth-containing quadruple therapy (BQT) has long been recommended for Helicobacter pylori (H. pylori) eradication in China. Meanwhile, in the latest national consensus in China, dual therapy (DT) comprising an acid suppressor and amoxicillin has also been recommended. In recent years, the eradication rate of H. pylori has reached >90% using DT, which has been used not only as a first-line treatment but also as a rescue treatment. Compared with BQT, DT has great potential for H. pylori eradication; however, it has some limitations. This review summarizes the development of DT and its application in H. pylori eradication. The H. pylori eradication rates of DT were comparable to or even higher than those of BQT or standard triple therapy, especially in the first-line treatment. The incidence of adverse events associated with DT was lower than that with other therapies. Furthermore, there were no significant differences in the effects of dual and quadruple therapies on gastrointestinal microecology. In the short term, H. pylori eradication causes certain fluctuations in the gastrointestinal microbiota; however, in the long term, the gastrointestinal microbiota eventually returns to its normal state. In the penicillin-naïve population, patients receiving DT have a high eradiation rate, better compliance, lower incidence of adverse reactions, and lower primary and secondary resistance to amoxicillin. These findings suggest the safety, efficacy, and potential of DT for H. pylori eradication.
format Online
Article
Text
id pubmed-10106215
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101062152023-04-17 Dual therapy for Helicobacter pylori infection Duan, Miao Liu, Jing Zuo, Xiuli Chin Med J (Engl) Review Articles Bismuth-containing quadruple therapy (BQT) has long been recommended for Helicobacter pylori (H. pylori) eradication in China. Meanwhile, in the latest national consensus in China, dual therapy (DT) comprising an acid suppressor and amoxicillin has also been recommended. In recent years, the eradication rate of H. pylori has reached >90% using DT, which has been used not only as a first-line treatment but also as a rescue treatment. Compared with BQT, DT has great potential for H. pylori eradication; however, it has some limitations. This review summarizes the development of DT and its application in H. pylori eradication. The H. pylori eradication rates of DT were comparable to or even higher than those of BQT or standard triple therapy, especially in the first-line treatment. The incidence of adverse events associated with DT was lower than that with other therapies. Furthermore, there were no significant differences in the effects of dual and quadruple therapies on gastrointestinal microecology. In the short term, H. pylori eradication causes certain fluctuations in the gastrointestinal microbiota; however, in the long term, the gastrointestinal microbiota eventually returns to its normal state. In the penicillin-naïve population, patients receiving DT have a high eradiation rate, better compliance, lower incidence of adverse reactions, and lower primary and secondary resistance to amoxicillin. These findings suggest the safety, efficacy, and potential of DT for H. pylori eradication. Lippincott Williams & Wilkins 2023-01-05 2023-02-13 /pmc/articles/PMC10106215/ /pubmed/36805362 http://dx.doi.org/10.1097/CM9.0000000000002565 Text en Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Review Articles
Duan, Miao
Liu, Jing
Zuo, Xiuli
Dual therapy for Helicobacter pylori infection
title Dual therapy for Helicobacter pylori infection
title_full Dual therapy for Helicobacter pylori infection
title_fullStr Dual therapy for Helicobacter pylori infection
title_full_unstemmed Dual therapy for Helicobacter pylori infection
title_short Dual therapy for Helicobacter pylori infection
title_sort dual therapy for helicobacter pylori infection
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106215/
https://www.ncbi.nlm.nih.gov/pubmed/36805362
http://dx.doi.org/10.1097/CM9.0000000000002565
work_keys_str_mv AT duanmiao dualtherapyforhelicobacterpyloriinfection
AT liujing dualtherapyforhelicobacterpyloriinfection
AT zuoxiuli dualtherapyforhelicobacterpyloriinfection